A Phase I/Ib Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer

Trial Profile

A Phase I/Ib Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2015

At a glance

  • Drugs Radium 223 chloride (Primary) ; Tasquinimod (Primary)
  • Indications Adenocarcinoma; Bone metastases; Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Apr 2015 After an interim analysis of the phase III 10TASQ10 study showed that tasquinimod did not improve overall survival, and efficacy results together with preliminary safety data did not support a positive benefit-risk balance in this population, Active Biotech and Ipsen announced their decision to discontinue the development of tasquinimod in prostate cancer, according to a media release.
    • 16 Apr 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, according to a media release from Active Biotech and Ipsen.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top